TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20059357

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TDV), 3 injections at months 0, 4, and 12-15
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tetravalent dengue vaccine (TDV), 2 injections at months 4 and 12-15
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (TDV)
Number of subjects: 66
Study: 17278979

Group type: EXPERIMENTAL
Intervention: Low-salt intake (50 mmol/day)
Number of subjects: 39
Study: 15679762

Group type: EXPERIMENTAL
Intervention: Mesalazine pellets (1.5 g/day in three doses)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Mesalazine tablets (1.5 g/day in three doses)
Number of subjects: 233
Study: 12019381

Group type: COMPARATOR
Intervention: Control group (C): All aspirated blood returned into circulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Suction blood discarded group (S)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surfaces coated with phosphorylcholine group (S+P)
Number of subjects: 30
Study: 10225572

Group type: EXPERIMENTAL
Intervention: 500 mg tablet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL oral suspension
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL suspension (fasted)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 mg/5 mL suspension (fasted)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 500 mg/10 mL suspension (fed)
Number of subjects: 68
Study: 8846490

Group type: EXPERIMENTAL
Intervention: ParaSight-F test
Number of subjects: 358
Study: 2245092

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen-codeine combination
Number of subjects: 100
Study: 639430

Group type: EXPERIMENTAL
Intervention: 12 mg piretanide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30985725

Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 65

Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: TURP and HoLEP
Number of subjects: 65
Study: 29911792

Group type: EXPERIMENTAL
Intervention: Exercise with Life-Build-Line (LBL) device
Number of subjects: 10
Study: 26228672

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 40 mg and ezetimibe 10 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) added to atorvastatin therapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) added to combined therapy
Number of subjects: 86
Study: 22889325

Group type: EXPERIMENTAL
Intervention: Early leakage (EL) diagnosed during initial hospital stay (n = 27)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Late leakage (LL) diagnosed after hospital discharge (n = 18)
Number of subjects: 45
Study: 22428512

Group type: EXPERIMENTAL
Intervention: Perimenopausal Exercise Group (PEMEG)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Postmenopausal Exercise Group (POMEG)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Perimenopausal Control Group (PEMCG)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Postmenopausal Control Group (POMCG)
Number of subjects: 175
Study: 20046230

Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (aspirin 100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of antiplatelet and anticoagulation therapy (target INR: 2.0‐3.0; mean 2.4+/‐0.3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single antiplatelet therapy (aspirin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 20
Study: 16648530

Group type: EXPERIMENTAL
Intervention: Motivational interviewing/CBT
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 130
Study: 15547065

Group type: EXPERIMENTAL
Intervention: Heavy computer users with refractive errors
Number of subjects: 10202

Group type: COMPARATOR
Intervention: Subjects without refractive errors
Number of subjects: 10202
Study: 11405833

Group type: EXPERIMENTAL
Intervention: High-intensity laser treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low-intensity laser treatment
Number of subjects: 53
Study: 9210608

Group type: EXPERIMENTAL
Intervention: Combination of terlipressin (1-2 mg, i.v. bolus) with ANP (35 ng/kg, i.v. bolus followed by 15 ng x kg(‐1) x min(‐1) for 60 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Terlipressin alone (1-2 mg, i.v. bolus)
Number of subjects: 16
Study: 7957341

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Cyclophosphamide (PC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAC (Cisplatin plus Cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (after PAC or CAC therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study: 3659136

Group type: EXPERIMENTAL
Intervention: Prone spinal extension exercise, 20 repetitions each day for four weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no exercise).
Number of subjects: 36
Study: 31366649

Group type: EXPERIMENTAL
Intervention: Tailored rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardised strengthening programme
Number of subjects: 0
Study: 29333870

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (bike/cross-trainer/brisk walking for 45 minutes, three times/week)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (usual daily activities)
Number of subjects: 52
Study: 26691222

Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with complete macroscopic resection (RD0)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with residual disease of 1-10mm (RD1-10)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Debulking surgery (DS) with residual disease of >10mm (RD>10)
Number of subjects: 326

Group type: COMPARATOR
Intervention: No surgery (NoCS)
Number of subjects: 326
Study: 24613373

Group type: EXPERIMENTAL
Intervention: Transfixing technique
Number of subjects: 126

Group type: COMPARATOR
Intervention: Single wall technique
Number of subjects: 126
Study: 22682723

Group type: EXPERIMENTAL
Intervention: 24/4 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 21/7 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both regimens (24/4 and 21/7)
Number of subjects: 18
Study: 20697079

Group type: EXPERIMENTAL
Intervention: p16-positive tumors
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 185

Group type: COMPARATOR
Intervention: tirapazamine arm
Number of subjects: 185
Study: 18816238

Group type: EXPERIMENTAL
Intervention: High concentrations of total omega‐3 fatty acids, eicosapentaenoic and docosahexaenoic acids in red blood cells, and ornithine in plasma
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High total omega‐6 fatty acids
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low levels of docosahexaenoic acid, ornithine, and omega‐3 index; high total omega‐6 and omega‐3/omega‐6 ratios
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High levels of ornithine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Peak concentrations of fatty acids in red blood cells
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High levels of arginine
Number of subjects: 54
Study: 15593189

Group type: EXPERIMENTAL
Intervention: OPC‐28326 40 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: OPC‐28326 10 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11340365

Group type: EXPERIMENTAL
Intervention: Intranasal CCK-8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9175051

Group type: EXPERIMENTAL
Intervention: Dialyser containing PMMA membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialyser containing Gambrane membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialyser containing Cuprophan membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dialysers containing Cuprophan and Gambrane membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: All dialysers
Number of subjects: 0
Study: 7898992

Group type: EXPERIMENTAL
Intervention: Kinesthetic information during practice trials
Number of subjects: 20

Group type: COMPARATOR
Intervention: No kinesthetic information during practice trials
Number of subjects: 20
Study: 3036715

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg five times daily) for seven days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg three times daily) combined with prednisolone (0.7 mg/kg daily) for ten days
Number of subjects: 56
Study: 30613057

Group type: EXPERIMENTAL
Intervention: Integrated physical activity program (INT) - 12 weeks duration, including self-regulation, support, and policy-environmental strategies
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Integrated physical activity program (INT) - 12 weeks duration
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (CT) - no strategies received
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Education group (ED) - self-regulation strategies only
Number of subjects: 268
Study: 27005766

Group type: EXPERIMENTAL
Intervention: TABLETS intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 24748531

Group type: EXPERIMENTAL
Intervention: CAF + CHO (6 mg kg(-1) BW caffeine and 0.8 g kg(-1) BW carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 12
Study: 23876565

Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 200
Study: 20592124

Group type: EXPERIMENTAL
Intervention: Retinal coordinates during saccade planning
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Retinal coordinates during sensory processing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Retinal coordinates during saccade execution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonretinal coding
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Contralateral bias of activation in IPS and FEF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SEF
Number of subjects: 18
Study: 17936025

Group type: EXPERIMENTAL
Intervention: Active tension measured using surface electromyography in the positive position of the O'Brien test.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Passive tension measured using a load cell in the negative position of the O'Brien test.
Number of subjects: 17

Group type: COMPARATOR
Intervention: O'Brien test (both positions).
Number of subjects: 17
Study: 17012983

Group type: EXPERIMENTAL
Intervention: Levetiracetam (mean maximum dosage 862.50±279.19 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14610141

Group type: EXPERIMENTAL
Intervention: Manual assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation‐exsufflation
Number of subjects: 0
Study: 11060815

Group type: EXPERIMENTAL
Intervention: Intrathecal ziconotide
Number of subjects: 0
Study: 8765075

Group type: EXPERIMENTAL
Intervention: Hypoechoic ventral embryologic cephalic pancreas
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Positive group (hypoechoic pancreas)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Negative group (reference)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Overall pancreatic echogenicity
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Sex ratio of hypoechoic pancreas
Number of subjects: 446
Study: 1557976

Group type: EXPERIMENTAL
Intervention: Spatial uncertainty effect in stereoacuity tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal uncertainty effect in stereoacuity tests
Number of subjects: 0
Study: 3901208

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 20
Study: 31706345

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice per week for 12 sessions at specified acupoints)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 320
Study: 29743825

Group type: EXPERIMENTAL
Intervention: Creatine-electrolyte (CE) supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P) group
Number of subjects: 23
Study: 27238898

Group type: EXPERIMENTAL
Intervention: Normal-size enriched beef meal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Reduced-size enriched chicken meal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enriched meals (both normal and reduced size)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal-size meals
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reduced-size meals
Number of subjects: 120
Study: 25275577

Group type: EXPERIMENTAL
Intervention: IV lidocaine (bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/h, stopped 2 hours after surgery)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22541418

Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Daily infant nevirapine
Number of subjects: 2369

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2369
Study: 19915017

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Metformin (2000 mg/d)
Number of subjects: 78
Study: 17878815

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 12934987

Group type: EXPERIMENTAL
Intervention: Oral-loaded divalproex (20 or 30 mg/kg/day on days 1 and 2 followed by 20 mg/kg/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Oral-loaded divalproex
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard-titration divalproex
Number of subjects: 348

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 348

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 10729387

Group type: EXPERIMENTAL
Intervention: Homozygous wildtype LL/QQ genotype of PON1
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Total plasma cholesterol
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: LL/QQ genotype of PON1
Number of subjects: 186
Study: 8602748

Group type: EXPERIMENTAL
Intervention: Anticoagulants (international normalized ratio range, 2.8-4.8)
Number of subjects: 3404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3404
Study: 1394813

Group type: EXPERIMENTAL
Intervention: Early instillation of Adriamycin alone (Group A)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Early instillation of Adriamycin with oral administration of 5-fluorouracil (Group B)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Delayed instillation of Adriamycin alone (Group C)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Delayed instillation of Adriamycin with oral administration of 5-fluorouracil (Group D)
Number of subjects: 275
Study: 2983151

Group type: EXPERIMENTAL
Intervention: Radiation therapy and oral Levamisole
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radiation therapy only
Number of subjects: 25
Study: 31061511

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal adjustment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 15
Study: 28627930

Group type: EXPERIMENTAL
Intervention: Fenofibrate 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 60
Study: 25864750

Group type: EXPERIMENTAL
Intervention: Iontophoresis of the Chinese drug
Number of subjects: 296

Group type: COMPARATOR
Intervention: Medium frequency electrotherapy
Number of subjects: 296
Study: 23524368

Group type: EXPERIMENTAL
Intervention: Structured injury prevention program performed twice weekly for the entirety of the season (58 prevention sessions)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control season (2009‐2010)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intervention season (2008‐2009)
Number of subjects: 49
Study: 21778313

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 147
Study: 19636320

Group type: EXPERIMENTAL
Intervention: Light intensity resistance exercise training (3 times per week, 35-40 min per session)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 160
Study: 17877674

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (50 micrograms)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Vaginal misoprostol (50 micrograms)
Number of subjects: 170
Study: 14742367

Group type: EXPERIMENTAL
Intervention: Cough Trick (CT) procedure
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Cough Trick (Control)
Number of subjects: 20
Study: 10967152

Group type: COMPARATOR
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Formoterol (12 microg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8629926

Group type: EXPERIMENTAL
Intervention: Spastic group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 32
Study: 1351196

Group type: EXPERIMENTAL
Intervention: Personalized hospital practice (PHP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 100
Study: 6367635

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (23 mg, dissolved every 2 hours after an initial double dose)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30131280

Group type: EXPERIMENTAL
Intervention: Stroboscopic eyewear
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal vision (Control)
Number of subjects: 22
Study: 30247384

Group type: EXPERIMENTAL
Intervention: Midline spikes
Number of subjects: 123
Study: 26981934

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 932

Group type: COMPARATOR
Intervention: Control (expectant management)
Number of subjects: 932
Study: 24286966

Group type: EXPERIMENTAL
Intervention: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention
Number of subjects: 234
Study: 22590530

Group type: EXPERIMENTAL
Intervention: Infant cries (low and high distress)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Happy infant faces
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sad infant faces
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-distress cries
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-distress cries
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pink noise
Number of subjects: 17
Study: 20924011

Group type: EXPERIMENTAL
Intervention: 7.5% saline/6% dextran (hypertonic saline/dextran)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: 7.5% saline (hypertonic saline)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: 0.9% saline (normal saline)
Number of subjects: 1282

Group type: EXPERIMENTAL
Intervention: All groups (hypertonic saline/dextran, hypertonic saline, normal saline)
Number of subjects: 1282
Study: 18957124

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 35
Study: 15781758

Group type: EXPERIMENTAL
Intervention: Isotretinoin high dose (1.0 mg/kg per day) for 1 year followed by moderate dose (0.5 mg/kg per day) for 2 years
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Isotretinoin moderate dose (0.5 mg/kg per day) for 3 years
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 151
Study: 14520221

Group type: EXPERIMENTAL
Intervention: Enhanced contraceptive counseling, initial provision of contraception, and facilitated referral to a PCP
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group (condoms with spermicide and referral list only)
Number of subjects: 877
Study: 10648315

Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline IV (Control)
Number of subjects: 50
Study: 8879891

Group type: EXPERIMENTAL
Intervention: 600 mg of cefdinir once daily (QD) for 10 days
Number of subjects: 466

Group type: COMPARATOR
Intervention: 300 mg of cefdinir twice daily (BID) for 10 days
Number of subjects: 466
Study: 1379664

Group type: COMPARATOR
Intervention: Cisplatin 80 mg/M2 on day 1 and 5-fluorouracil 800 mg/M2 days 2 through 6 (two-drug regimen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/M2 on day 1, 5-fluorouracil 800 mg/M2 days 2 through 6, plus 15 U bleomycin on day 1 and methotrexate 100 mg/M2 on day 16 followed by 15 mg leucovorin every 6 hours for six doses (four-drug regimen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 62
Study: 31831364

Group type: EXPERIMENTAL
Intervention: Highest tertile of serum hepatocyte growth factor (HGF) in patients with dyslipidemia
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Highest tertile of serum hepatocyte growth factor (HGF) in patients with normal lipids
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Adding HGF to conventional risk factors in patients with dyslipidemia
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: HDL-C levels in ischemic stroke patients
Number of subjects: 3027
Study: 30600702

Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine only
Number of subjects: 12

Group type: COMPARATOR
Intervention: IL-2, GM-CSF, and rhGH immunotherapy with or without vaccine
Number of subjects: 12
Study: 28587609

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: BBTI
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: SHUTi
Number of subjects: 625

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 625